Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Publication year range
1.
J Natl Cancer Inst ; 82(8): 703-7, 1990 Apr 18.
Article in English | MEDLINE | ID: mdl-2181152

ABSTRACT

We performed a phase I-II trial of escalating doses of cisplatin (CDDP: 50-100 mg/m2 per course) plus carboplatin (CBDCA: 300-400 mg/m2 per course) as a potential way in which to maximize platinum doses without causing excessive toxic effects in patients with advanced ovarian cancer. Thirty-three patients with nonoptimally debulked disease of FIGO (International Federation of Gynecology and Obstetrics) stages IIc-IV [median age: 60 yr; median WHO (World Health Organization) performance status: 2; no prior chemotherapy] received a median of six courses of therapy. CBDCA was infused on day 1 and CDDP on day 2 with an aggressive 48-hour hydration regimen. Myelosuppression was dose-limiting: at the highest dose levels, WHO grade 4 neutropenia and thrombocytopenia led to dose reduction and/or treatment delay in 45% of the patients. Nonhematologic toxic effects included acute nausea and vomiting (97% of the patients), mild alopecia (45%), ototoxic effects (39%), neurotoxic effects (21%), and renal toxic effects (serum creatinine greater than 1.5 mg/dL: 12.5%). The pathologic complete response rate was 22%. We conclude that CBDCA and CDDP can be given safely in combination at reasonably high doses (CBDCA at 300 mg/m2 per course and CDDP at 100 mg/m2 per course) over a 6-month period, provided a close hematologic follow-up is conducted. Randomized clinical trials are needed to define whether this regimen is any better than standard combination chemotherapy.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Cisplatin/administration & dosage , Organoplatinum Compounds/administration & dosage , Ovarian Neoplasms/drug therapy , Adult , Aged , Bone Marrow/drug effects , Carboplatin , Cisplatin/adverse effects , Female , Humans , Middle Aged , Organoplatinum Compounds/adverse effects
3.
Eur J Obstet Gynecol Reprod Biol ; 9(2): 125-7, 1979 Apr.
Article in English | MEDLINE | ID: mdl-400865

ABSTRACT

From an open comparative multicentric trial it became clear that econazole was an active and well-tolerated agent for the treatment of vulvo-vaginal mycoses. Combined treatment with pessaries and econazole cream seems to be worthwhile in order to isolate the vagina from possible Candida reservoirs or to hasten symptomatic relief.


Subject(s)
Candidiasis, Vulvovaginal/drug therapy , Econazole/therapeutic use , Imidazoles/therapeutic use , Adolescent , Adult , Aged , Aged, 80 and over , Clinical Trials as Topic , Econazole/administration & dosage , Female , Humans , Middle Aged , Pessaries , Pregnancy , Pregnancy Complications, Infectious/drug therapy , Random Allocation , Vaginal Creams, Foams, and Jellies
SELECTION OF CITATIONS
SEARCH DETAIL
...